France· FR:60991573
ACLOTINE 100 UI/mL, poudre et solvant pour solution injectable
A medicinal product, registered in France by LFB-BIOMEDICAMENTS.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Manufacturer
- LFB-BIOMEDICAMENTS
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009561937141 flacon(s) en verre de poudre - 1 flacon(s) en verre de solvant de 5 ml avec dispositif de transfert
- cip1334009561938821 flacon(s) en verre de poudre - 1 flacon(s) en verre de solvant de 10 ml avec dispositif de transfert
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
ACLOTINE in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandAnbinexInstituto Grifols S.A.
- CzechiaANBINEXInstituto Grifols, S.A., Barcelona
- SpainANBINEX POLVO Y DISOLVENTE PARA SOLUCION PARA PERFUSIONInstituto Grifols S.A.
- SwitzerlandAtenativ 1000 I.E., Pulver und Lösungsmittel zur Herstellung einer InfusionslösungOctapharma AG
- NorwayAtenativOctapharma AB
- BelgiumAtenativ 1000 IUOctapharma Benelux
- SwedenAntithrombin III Baxalta Pulver och vätska till injektions-/infusionsvätska, lösningBaxalta Innovations GmbH
- GermanyAnbinexGrifols Deutschland Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Antithrombin Iii Takeda, Atenativ
- Belgium · Antithrombin Iii Konzentrat Baxalta, Antitrombine Iii-Concentraat Baxalta
- Bulgaria · Антитромбин Iii Nf Получен От Човешка Плазма Баксалта, Атенатив
- Czechia · Anbinex, Antithrombin Iii Baxalta
- Germany · Anbinex, Atenativ
- Denmark · Antitrombin Iii Baxalta, Atenativ
- Estonia · Atenativ
- Spain · Anbinex, Kybernin P
- Finland · Atenativ
- Greece · Kybernin P
- Croatia · Antithrombin Iii Baxalta, Atenativ
- Hungary · Antithrombin Iii Baxalta, Atenativ
- Italy · Anbinex, Anternaty
- Lithuania · Atenativ
- Luxembourg · Kybernin P
- Latvia · Atenativ
- Malta · Antithrombin Iii Baxalta
- Netherlands · Antitrombine Iii Concentraat Baxalta, Atenativ
- Norway · Atenativ
- Poland · Anbinex, Antithrombin Iii Nf Takeda
- Portugal · Anbinex, Atenativ
- Romania · Atenativ
- Sweden · Antithrombin Iii Baxalta, Antithrombin Iii Octapharma
- Slovenia · Atenativ, Kybernin P
- Slovakia · Anbinex, Antithrombin Iii Ľudský Antitrombín Iii Získaný Z Plazmy Baxalta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a449dcd7-d7d6-4931-b68b-25641de74481 GET /v1/drugs/a449dcd7-d7d6-4931-b68b-25641de74481?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60991573",
"date_amm": "1998-12-30",
"type_amm": "Procédure nationale",
"numero_ue": null,
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre et solvant pour solution injectable",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ACLOTINE.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.